Clinical trials: Adebrelimab
Pancreatic Cancer
Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study
Pancreatic cancer is a highly malignant digestive system tumor with a very poor prognosis. In recent years, both the incidence and mortality rates of pancreatic cancer have shown a marked upward trend worldwide.
- Trial name
- NCT07542002
- Testing
- Irinotecan liposome, 5-fluorouracil/leucovorin, and oxaliplatin, with or without adadelimab.
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Gastric Cancer
Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
To evaluate the efficacy and safety of adebrelimab combined DOS in neoadjuvant treatment of locally advanced resectable gastric cancer.
- Trial name
- NCT06475417
- Testing
- Adebrelimab combined with DOS
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Tang-Du Hospital
Liver Cancer (Primary and Metastatic)
A Study of Combination Therapy in Patients With Resectable Liver Cancer
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of an initial combination treatment strategy followed by surgery in patients with cancer.
- Trial name
- Archer (NCT07684040)
- Testing
- Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma
Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study
This is a randomized, non-comparative, open-label, two-arm phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab plus induction chemotherapy versus adebrelimab plus SHR-8086…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors, Immunotherapy
- Trial name
- CATALIS (NCT07266025)
- Testing
- Adebrelimab, XELOX, SHR-8068
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Non Small Cell Lung Cancer
Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
Although phase III studies have confirmed the efficacy and safety of perioperative immunotherapy plus chemotherapy for resectable NSCLC, there remains room for improvement in both short-term efficacy and long-term survival.
- Trial name
- NCT07567326
- Testing
- Adebrelimab, Retlirafusp alfa, Recaticimab and chemotherapy
- Volunteers
- 78 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Cancer
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
To assess the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (with symptomatic dysphagia or oligometastatic…
- Trial name
- NCT06464614
- Testing
- Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC)
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Thyroid Cancer
Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
This is a multi-cohort, open-label, single-centre, Phase 2 study aiming to investigate the efficacy and safety of a regimen using the multi-targeted kinase inhibitor Famitinib in combination with the PD-L1 antibody Adebrelimab…
- Trial name
- NCT06146985
- Testing
- 20 mg Famitinib & 1200 mg Adebrelimab
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Neuroendocrine Carcinoma of the Bladder, Bladder Cancer
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
The goal of this clinical trial is to learn about the efficacy and safety of neoadjuvant adebrelimab plus etoposide and cisplatin in patients with neuroendocrine bladder carcinoma.
- Trial name
- NEOBLAST (NCT06091124)
- Testing
- Adebrelimab, Etoposide, Cisplatin
- Where
- 5 sites in China
- Volunteers
- 22 people
- Sponsor
- RenJi Hospital
Advanced or Metastatic Non-small Cell Lung Cancer
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer.
- Trial name
- NCT06512051
- Testing
- SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injection
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Adebrelimab, Adenocarcinoma of GE Junction
Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
This is a prospective, single-center, single-arm, open phase II clinical study. Forty-nine participants with pathologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer are scheduled to be…
- Conditions
- Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of Stomach
- Trial name
- NCT07353684
- Testing
- Adebrelimab, Apatinib, SOX Chemotherapy
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Friendship Hospital
Esophageal Squamous Cell Carcinoma, Immunotherapy
Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
- Trial name
- RICE (NCT06510660)
- Testing
- adebrelimab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Fujian Medical University Union Hospital
Metastatic Colorectal Cancer
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
Metastatic colorectal cancer with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) molecular phenotypes could significantly benefit from immune checkpoint inhibitor therapy, ushering in the MSI era of…
- Trial name
- NCT07718490
- Testing
- Adebrelimab
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Investigators plan to conduct a single-arm clinical study of adebelimab, a novel PD-L1 inhibitor, in the neoadjuvant treatment of early or locally advanced high-risk ER+/HER2- breast cancer, to explore whether the addition of…
- Trial name
- NCT06500208
- Testing
- Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Esophageal Cancer (EsC)
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled and treated with adebrelimab (SHR-1316) combined…
- Trial name
- NCT06869213
- Testing
- Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Gastric Cancer, Surgery
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Exploring the pathological complete response rate (pCR) of locally advanced gastric cancer treated with adebelimab combined or not combined with apatinib mesylate and SOX neoadjuvant therapy
- Trial name
- SOP-XH-IRB (NCT07314203)
- Testing
- Apatinib Mesylate Tablets
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Fujian Medical University
Biliary Tract Neoplasms Immunotherapy
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
An investigation into the survival outcomes, progression-free survival, and safety of triple therapy with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib in patients with advanced HER2-positive/low-expressing biliary tract…
- Trial name
- NCT07704177
- Testing
- Trastuzumab Rezetecan, Adebrelimab, Lenvatinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Breast Cancer
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.
- Trial name
- NCT06433609
- Testing
- SHR-A1811, SHR-A1921, Adebrelimab
- Where
- China
- Volunteers
- 113 people
- Sponsor
- Beijing GoBroad Hospital
HNSCC
Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
This single-center, open-label Phase II trial aims to evaluate the efficacy and safety of neoadjuvant combination therapy with Adebrelimab (anti-PD-L1), Dalpiciclib Isethionate (CDK4/6 inhibitor), and cisplatin chemotherapy in…
- Trial name
- NCT07778732
- Testing
- Adebrelimab Injection, Dalpiciclib Isethionate, Cisplatin
- Volunteers
- 32 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Hypopharyngeal Cancer
Neoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen
To evaluate the efficacy and safety of adebrelimab combined with TP chemotherapy regimen as neoadjuvant therapy for locally advanced hypopharyngeal cancer
- Trial name
- NCT07137039
- Testing
- Adebrelimab+Albumin paclitaxel +Cisplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Platinum-sensitive Relapsed Ovarian Cancer
Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus chemotherapy and bevacizumab induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib (PARP inhibitor)and…
- Trial name
- NCT06446206
- Testing
- Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
- Volunteers
- 22 people
- Sponsor
- The First Hospital of Jilin University